Related Experiment Video
Updated: May 8, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Seroprotection after hepatitis a vaccination in patients with drug-induced immunosuppression
Wouter van den Bijllaardt1, Helen M Siers, Caroline Timmerman-Kok
1Department of Infectious Diseases, Public Health Service (GGD) Gelre-IJssel, Apeldoorn, The Netherlands.
Background:
Increasing numbers of travelers using immunosuppressive drugs visit hepatitis A endemic countries. Data on protection rates after hepatitis A vaccination in this group are scarce.
Methods:
In this retrospective study, records of subjects with hepatitis A serology taken after vaccination were searched for in travel clinic databases. Relation between immunosuppressive drug use, age, gender, and time between vaccination and serology was evaluated.
Results:
Seroprotection rates within 4 weeks after primary vaccination (50%) are lower than after 4 weeks (64%). After the complete series of two vaccinations seroprotection rates reach 95% although success depends on the immunosuppressive drug being used. Subjects under anti-TNF alpha treatment have significantly lower seroprotection rates than subjects using classical immunosuppressive drugs after the second vaccination. There is no influence of age or gender on seroprotection rates.
Conclusions:
Last-minute vaccination in subjects using immunosuppressive medication is not reliable, only 60% of our subjects had a protective antibody level after a single vaccination. When serology was done within 4 weeks after a single vaccination, seroprotection rates were only 50%, after 4 weeks this number rose to 64%. When persons visit a travel clinic in time for a complete vaccination series, satisfactory seroprotection rates can be reached. Seroprotection rate depends on the drug being used, persons using anti-TNF alpha are less protected.
Related Concept Videos
Hepatitis
Drug Toxicity: Allergic Reactions
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Vaccinations
Cross-reactivity

